Entrada Therapeutics, Inc. (TRDA) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 4 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for TRDA is $18.00, representing a +28.3% upside from the current price of $14.03. Price targets range from a low of $13.00 to a high of $21.00.
